BIPAR SCIENCES

BiPar Sciences Inc. is a Brisbane, CA based developer of PARP inhibitors as cancer therapies. BiPar's key experimental product is BSI-201, currently in mid-stage trials for advanced breast cancer, ovarian cancer and other tumors. BiPar has raised around $60 million in VC funding, from firms like [Domain Associates](/financial-organization/domain-associates), [Canaan Partners](/financial-organization/canaan-partners-3), [Vulcan Capital](/financial-organization/vulcan-capital), [PolyTechnos Ven... ture Partners](/financial-organization/polytechnos-venture-partners), [Asset Management Company](/financial-organization/asset-management), and [Quantum Technology Partners](/financial-organization/quantum-technology-partners). It also has raised venture debt from [Lighthouse Capital Partners](/financial-organization/lighthouse-capital-partners). On April 15th, 2009, French drug maker [Sanofi-Aventis S.A.](/organization/sanofi-aventis-2) announced it was acquiring BiPar Sciences for up to $500 million.More